---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-086606"
form_type: "8-K"
ticker: "MDAI"
cik: "0001833498"
company_name: "Spectral AI, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:58:56.537926+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spectral AI Q3 revenue $3.4M, net loss $10.6M; affirms FY2023 guidance $17.4M

## Summary
- Q3 revenue $3.4M (down 51% YoY); net loss $10.6M ($0.77/share) vs loss $0.4M in Q3 2022.
- Adjusted EBITDA loss $3.9M vs $0.0M; non-recurring transaction costs $7.6M from Nasdaq listing.
- Cash $7.3M, no long-term debt; reaffirms FY2023 revenue ~$17.4M and FY2024 ~$28.0M.
- Received $149M U.S. government contract for DeepView System burn indication (total govt awards >$246M).
- Plans to submit FDA/UKCA/CE mark apps for DFU and 3D wound measurement in 2024; burn in 2025.

## SEC filing metadata
- accession: 0001213900-23-086606
- form_type: 8-K
- ticker: MDAI
- cik: 0001833498
- company_name: Spectral AI, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833498/000121390023086606/0001213900-23-086606-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833498/000121390023086606/ea188358-8k_spectral.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-086606
- JSON: https://secwatch.observer/filing/0001213900-23-086606.json
- Plain text: https://secwatch.observer/filing/0001213900-23-086606.txt

## Key facts
- Earnings Releases
  Spectral AI, Inc. reported the third quarter ended September 30, 2023 results: revenue $3.4 million, net income Net loss was $(10.6) million, EPS $(0.77) per share. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $3.4 million
  - Net income: Net loss was $(10.6) million
  - EPS: $(0.77) per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Q3 2023 FINANCIAL RESULTS OVERVIEW All comparisons are to the third quarter ended September 30, 2022 (“Q3 2022”) unless otherwise stated. ● Research & Development Revenue 1 was $3.4 million compared to $7.0 million, primarily due to decreased research and development work performed pursuant to the BARDA Burn II contract as clinical trials under this contract were
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833498/000121390023086606/0001213900-23-086606-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.